[利拉鲁肽治疗普拉德-威利综合征患者的肥胖症：一例报告]
[Obesity treatment with liraglutide in a patient with Prader-Willi syndrome: a case report].
作者信息
Cadena-Obando Diego Andrés, Molina-Ayala Mario Antonio, Ferreira-Hermosillo Aldo
机构信息
Servicio de Endocrinología. Hospital de Especialidades. Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social.
出版信息
Nutr Hosp. 2018 May 21;35(3):743-746. doi: 10.20960/nh.1525.
BACKGROUND
Prader-Willi syndrome (PWS) is a major cause of syndromic obesity, caused by deletions on chromosome 15q11-q13. It is characterized by neonatal hypotonia, difficulty in feeding with low birth-weight and subsequent development of hyperphagia, behavioral disorders and obesity. Treatment options for weight control in those patients is limited and there are controversies for a surgical approach.
CASE REPORT
we present the case of a patient with PWS who achieved weight loss and control through the use of liraglutide, nutritional therapy and physical activity.
DISCUSSION
the treatment of obesity in patients with PWS is challenging and requires an adequate nutritional approach combined with psychological therapy. In those patients that persist with uncontrolled appetite, medications such as metformin or GLP-1 analogs can be used.
背景
普拉德-威利综合征（PWS）是综合征性肥胖的主要原因，由15号染色体q11-q13区域的缺失引起。其特征为新生儿肌张力减退、喂养困难、低出生体重，随后出现食欲亢进、行为障碍和肥胖。这些患者控制体重的治疗选择有限，手术治疗方法存在争议。
病例报告
我们报告一例普拉德-威利综合征患者通过使用利拉鲁肽、营养治疗和体育活动实现体重减轻和控制的病例。
讨论
普拉德-威利综合征患者的肥胖治疗具有挑战性，需要适当的营养方法并结合心理治疗。对于那些食欲持续无法控制的患者，可以使用二甲双胍或GLP-1类似物等药物。
Zotero 插件